Attention, cette opération peut prendre du temps
et vous ne devez pas quitter cette page.

Vous êtes ici

Biblio

4 resultats trouvés

Filtres: Auteur is Lemasson, H. [Clear All Filters]

I

Anota A., Pozet A., Lefevre C., Lemasson H., Cotte F-E., Guerzider S., Mouillet G., Eberst G., Charton E., Westeel V.. 2019. Impact of open-label design on patient-reported outcomes (PROs) data in randomized clinical trials of immuno-oncology (IO) agents in patients with advanced or metastatic cancer: A 10-year systematic literature review (SLR). ANNALS OF ONCOLOGY. 30

Anota A., Pozet A., Lefevre C., Lemasson H., Cotte F-E., Guerzider S., Mouillet G., Eberst G., Charton E., Westeel V.. 2019. Impact of open-label design on patient-reported outcomes (PROs) data in randomized clinical trials of immuno-oncology (IO) agents in patients with advanced or metastatic cancer: A 10-year systematic literature review (SLR). ANNALS OF ONCOLOGY. 30

Westeel V., Bourdon M., Cortot A.B, Debieuvre D., Toffart A.C, Acquadro M., Arnould B., Lambert J., Cotte F-E., Gaudin A-F. et al.. 2020. Integrating patients' quality of life (QoL) into clinical practice: A Delphi method-based consensus among French physicians managing lung cancer patients. ANNALS OF ONCOLOGY. 31:S956.

M

Westeel V., Bourdon M., Cortot A.B, Debieuvre D., Toffart A.-C, Acquadro M., Arnould B., Lambert J., Cotte F.-E, Gaudin A.-F et al.. 2021. Management of lung cancer patients' quality of life in clinical practice: a Delphi study. ESMO OPEN. 6:100239.